The Lyssiotis lab uses a multi-disciplinary approach encompassing methods in chemistry and biology to define how metabolism is rewired in cancer. This work spans the areas of cancer metabolism, the tumor microenvironment and immunometabolism using and developing protocols in mass spectrometry-based metabolomics. Ultimately, we aim to transition new information about these processes into targeted therapies for cancer and other diseases. Please explore our website for more information.

Costas A. Lyssiotis obtained his bachelor’s degree in chemistry and biochemistry from the University of Michigan in 2004. As a NSF Predoctoral fellow, Costas earned a PhD with Peter G Schultz at TSRI in 2010. There, he discovered new drug-like molecules that convert differentiated cells into stem cells for use in degenerative disease. In 2010, Costas joined the laboratory of Lewis C. Cantley at Harvard Medical School as the Amgen fellow of the Damon Runyon Cancer Research Foundation and was later awarded a Pancreatic Cancer Action Network Pathway to Leadership Grant.

Dr. Lyssiotis is currently a Professor at the University of Michigan Medical School with appointments in the Departments of Molecular & Integrative Physiology. His lab, located in the Rogel Cancer Center, studies the biochemical pathways and metabolic requirements that enable tumor survival and growth and, in particular, how this information can be used to design targeted therapies. Among his many contributions, Dr. Lyssiotis has defined several new metabolic pathways in pancreatic cancer cells and tumors that are required for growth. For this work, he has been awarded the Dale F. Frey Award for Breakthrough Scientists, the Tri-Institutional Breakout Prize for Junior Investigators and the American Gastroenterological Association Augustyn Award in Digestive Cancer. He is also a Sidney Kimmel Foundation Junior Scholar, a Lefkofsky Family Foundation Scholar, a Melanoma Research Alliance Young Investigator and a V Foundation Junior Scholar.